MRNA is trading up 4.99% at $33.77 following Moderna's announcement of regulatory submissions for its seasonal flu vaccine, mRNA-1010.
- The company filed for marketing authorization with the FDA, EMA, Health Canada, and TGA in Australia for adults aged 50 and older.
- Phase 3 data indicated the vaccine achieved 26.6% relative efficacy compared to standard-dose flu shots, with a favorable safety profile.
- This product is viewed as a critical revenue driver as the company seeks to rebound from recent COVID and RSV vaccine sales challenges.